We narrowed to 60 results for: alp

1. pAAV-double floxed-eNpHR-EYFP-WPRE-pA (AAV9)

   Viral Prep

   #20949-AAV9

   Purpose

   Ready-to-use AAV9 particles produced from pAAV-double floxed-eNpHR-EYFP-WPRE-pA (#20949). In addition to the viral particles, you will also receive purified pAAV-double floxed-eNpHR-EYFP-WPRE-pA plasmid DNA. EF1a-driven, cre-dependent eNpHR EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Karl Deisseroth

   Promoter

   EF1a

   Tags

   EYFP (Cre-dependent)

   Available since

   July 12, 2018

   Availability

   Academic Institutions and Nonprofits only

2. pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (AAV8)

   Viral Prep

   #20297-AAV8

   Purpose

   Ready-to-use AAV8 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (#20297). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA plasmid DNA. Humanized channelrhodopsin H134R mutant fused to mCherry, driven by the EF1a promoter. Cre-dependent. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Karl Deisseroth

   Promoter

   EF1a

   Tags

   mCherry (Cre-dependent)

   Available since

   Dec. 18, 2017

   Availability

   Academic Institutions and Nonprofits only

3. pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (AAV1)

   Viral Prep

   #20297-AAV1

   Purpose

   Ready-to-use AAV1 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (#20297). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA plasmid DNA. Humanized channelrhodopsin H134R mutant fused to mCherry, driven by the EF1a promoter. Cre-dependent. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Karl Deisseroth

   Promoter

   EF1a

   Tags

   mCherry (Cre-dependent)

   Available since

   Feb. 15, 2018

   Availability

   Academic Institutions and Nonprofits only

4. pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (AAV9)

   Viral Prep

   #20297-AAV9

   Purpose

   Ready-to-use AAV9 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (#20297). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA plasmid DNA. Humanized channelrhodopsin H134R mutant fused to mCherry, driven by the EF1a promoter. Cre-dependent. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Karl Deisseroth

   Promoter

   EF1a

   Tags

   mCherry (Cre-dependent)

   Available since

   March 15, 2018

   Availability

   Academic Institutions and Nonprofits only

5. pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (AAV5)

   Viral Prep

   #20297-AAV5

   Purpose

   Ready-to-use AAV5 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (#20297). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA plasmid DNA. Humanized channelrhodopsin H134R mutant fused to mCherry, driven by the EF1a promoter. Cre-dependent. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Karl Deisseroth

   Promoter

   EF1a

   Tags

   mCherry (Cre-dependent)

   Available since

   Feb. 15, 2018

   Availability

   Academic Institutions and Nonprofits only

6. pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (AAV1)

   Viral Prep

   #20298-AAV1

   Purpose

   Ready-to-use AAV1 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (#20298). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA plasmid DNA. EF1a-driven, Cre-dependent, humanized channelrhodopsin H134R mutant fused to EYFP, for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Karl Deisseroth

   Promoter

   EF1a

   Tags

   EYFP (Cre-dependent)

   Available since

   Oct. 12, 2017

   Availability

   Academic Institutions and Nonprofits only

7. pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (AAV9)

   Viral Prep

   #20298-AAV9

   Purpose

   Ready-to-use AAV9 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (#20298). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA plasmid DNA. EF1a-driven, Cre-dependent, humanized channelrhodopsin H134R mutant fused to EYFP, for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Karl Deisseroth

   Promoter

   EF1a

   Tags

   EYFP (Cre-dependent)

   Available since

   March 30, 2018

   Availability

   Academic Institutions and Nonprofits only

8. pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (AAV5)

   Viral Prep

   #20298-AAV5

   Purpose

   Ready-to-use AAV5 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (#20298). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA plasmid DNA. EF1a-driven, Cre-dependent, humanized channelrhodopsin H134R mutant fused to EYFP, for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Karl Deisseroth

   Promoter

   EF1a

   Tags

   EYFP (Cre-dependent)

   Available since

   Feb. 15, 2018

   Availability

   Academic Institutions and Nonprofits only

9. pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (AAV Retrograde)

   Viral Prep

   #20298-AAVrg

   Purpose

   Ready-to-use AAV Retrograde particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (#20298). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA plasmid DNA. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Karl Deisseroth

   Promoter

   EF1a

   Tags

   EYFP (Cre-dependent)

   Available since

   Oct. 12, 2017

   Availability

   Academic Institutions and Nonprofits only

10. pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (AAV Retrograde)

    Viral Prep

    #20297-AAVrg

    Purpose

    Ready-to-use AAV Retrograde particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (#20297). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA plasmid DNA. Humanized channelrhodopsin H134R mutant fused to mCherry, driven by the EF1a promoter. Cre-dependent. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Karl Deisseroth

    Promoter

    EF1a

    Tags

    mCherry (Cre-dependent)

    Available since

    Aug. 22, 2017

    Availability

    Academic Institutions and Nonprofits only

11. pAAV-Ef1a-DIO ChETA-EYFP (AAV5)

    Viral Prep

    #26968-AAV5

    Purpose

    Ready-to-use AAV5 particles produced from pAAV-Ef1a-DIO ChETA-EYFP (#26968). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO ChETA-EYFP plasmid DNA. EF1a-driven, Cre-dependent, ChETA fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Karl Deisseroth

    Article

    Gunaydin et al Nat Neurosci. 2010 Mar;13(3):387-92. doi

    Promoter

    EF1a

    Tags

    EYFP (Cre-dependent)

    Available since

    Feb. 20, 2018

    Availability

    Academic Institutions and Nonprofits only

12. pAAV-Ef1a-DIO ChETA-EYFP (AAV9)

    Viral Prep

    #26968-AAV9

    Purpose

    Ready-to-use AAV9 particles produced from pAAV-Ef1a-DIO ChETA-EYFP (#26968). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO ChETA-EYFP plasmid DNA. EF1a-driven, Cre-dependent, ChETA fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Karl Deisseroth

    Article

    Gunaydin et al Nat Neurosci. 2010 Mar;13(3):387-92. doi

    Promoter

    EF1a

    Tags

    EYFP (Cre-dependent)

    Available since

    March 30, 2018

    Availability

    Academic Institutions and Nonprofits only

13. pAAV-Ef1a-DIO ChETA-EYFP (AAV1)

    Viral Prep

    #26968-AAV1

    Purpose

    Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO ChETA-EYFP (#26968). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO ChETA-EYFP plasmid DNA. EF1a-driven, Cre-dependent, ChETA fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Karl Deisseroth

    Article

    Gunaydin et al Nat Neurosci. 2010 Mar;13(3):387-92. doi

    Promoter

    EF1a

    Tags

    EYFP (Cre-dependent)

    Available since

    Feb. 21, 2018

    Availability

    Academic Institutions and Nonprofits only

14. pAAV-Ef1a-DIO eNpHR 3.0-EYFP (AAV5)

    Viral Prep

    #26966-AAV5

    Purpose

    Ready-to-use AAV5 particles produced from pAAV-Ef1a-DIO eNpHR 3.0-EYFP (#26966). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO eNpHR 3.0-EYFP plasmid DNA. EF1a-driven, cre-dependent eNpHR 3.0-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Karl Deisseroth

    Article

    Gradinaru et al Cell. 2010 Apr 2. 141(1):154-65.

    Promoter

    EF1a

    Tags

    EYFP (Cre-dependent)

    Available since

    Feb. 14, 2018

    Availability

    Academic Institutions and Nonprofits only

15. pAAV-Ef1a-DIO eNpHR 3.0-EYFP (AAV9)

    Viral Prep

    #26966-AAV9

    Purpose

    Ready-to-use AAV9 particles produced from pAAV-Ef1a-DIO eNpHR 3.0-EYFP (#26966). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO eNpHR 3.0-EYFP plasmid DNA. EF1a-driven, cre-dependent eNpHR 3.0-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Karl Deisseroth

    Article

    Gradinaru et al Cell. 2010 Apr 2. 141(1):154-65.

    Promoter

    EF1a

    Tags

    EYFP (Cre-dependent)

    Available since

    April 6, 2018

    Availability

    Academic Institutions and Nonprofits only

16. pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (AAV PHP.eB)

    Viral Prep

    #20298-PHPeB

    Purpose

    Ready-to-use AAV PHP.eB particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (#20298). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA plasmid DNA. EF1a-driven, Cre-dependent, humanized channelrhodopsin H134R mutant fused to EYFP, for optogenetic activation. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Karl Deisseroth

    Promoter

    EF1a

    Tags

    EYFP (Cre-dependent)

    Available since

    Sept. 8, 2020

    Availability

    Academic Institutions and Nonprofits only

17. pAAV-Ef1a-DIO eNpHR 3.0-EYFP (AAV1)

    Viral Prep

    #26966-AAV1

    Purpose

    Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO eNpHR 3.0-EYFP (#26966). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO eNpHR 3.0-EYFP plasmid DNA. EF1a-driven, cre-dependent eNpHR 3.0-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Karl Deisseroth

    Article

    Gradinaru et al Cell. 2010 Apr 2. 141(1):154-65.

    Promoter

    EF1a

    Tags

    EYFP (Cre-dependent)

    Available since

    Feb. 14, 2018

    Availability

    Academic Institutions and Nonprofits only

18. pAAV-Ef1a-DIO eNpHR 3.0-EYFP (AAV Retrograde)

    Viral Prep

    #26966-AAVrg

    Purpose

    Ready-to-use AAV Retrograde particles produced from pAAV-Ef1a-DIO eNpHR 3.0-EYFP (#26966). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO eNpHR 3.0-EYFP plasmid DNA. EF1a-driven, cre-dependent eNpHR 3.0-EYFP for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Karl Deisseroth

    Article

    Gradinaru et al Cell. 2010 Apr 2. 141(1):154-65.

    Promoter

    EF1a

    Tags

    EYFP (Cre-dependent)

    Available since

    March 27, 2024

    Availability

    Academic Institutions and Nonprofits only

19. pAAV-EF1a-iCreV (AAV1)

    Viral Prep

    #140135-AAV1

    Purpose

    Ready-to-use AAV1 particles produced from pAAV-EF1a-iCreV (#140135). In addition to the viral particles, you will also receive purified pAAV-EF1a-iCreV plasmid DNA. EF1a-driven, light-inducible iCreV recombinase for spatiotemporally precise optogenomic modifications. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Hongkui Zeng

    Article

    Yao et al Nat Methods. 2020 Mar 23. pii: 10.1038/s

    Promoter

    EF1a

    Tags

    None

    Available since

    Sept. 15, 2021

    Availability

    Academic Institutions and Nonprofits only

20. pAAV-EF1a-iCreV (AAV PHP.eB)

    Viral Prep

    #140135-PHPeB

    Purpose

    Ready-to-use AAV PHP.eB particles produced from pAAV-EF1a-iCreV (#140135). In addition to the viral particles, you will also receive purified pAAV-EF1a-iCreV plasmid DNA. EF1a-driven, light-inducible iCreV recombinase for spatiotemporally precise optogenomic modifications. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Hongkui Zeng

    Article

    Yao et al Nat Methods. 2020 Mar 23. pii: 10.1038/s

    Promoter

    EF1a

    Tags

    None

    Available since

    Sept. 15, 2021

    Availability

    Academic Institutions and Nonprofits only